Cabergoline and the risk of valvular lesions in endocrine disease

European Journal of Endocrinology

Volumn 159, Issue 1, 2008, Pages 1-5

  Lancellotti, Patrizio ^a   Livadariu, Elena ^a   Markov, Muriel ^a   Daly, Adrian F ^a   Burlacu, Maria Cristina ^a   Betea, Daniela ^a   Pierard, Luc ^a   Beckers, Albert ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE;

ADULT; AGED; AORTA VALVE DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; ECHOCARDIOGRAPHY; FEMALE; HEART VALVE REGURGITATION; HUMAN; HYPERPROLACTINEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TRICUSPID VALVE DISEASE; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DRUG EFFECT; ENDOCRINE DISEASE; MIDDLE AGED; MITRAL VALVE; PATHOLOGY; VALVULAR HEART DISEASE;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DOPAMINE AGONISTS; ECHOCARDIOGRAPHY; ENDOCRINE SYSTEM DISEASES; ERGOLINES; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; RISK FACTORS;

EID: 47049126778     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0213     Document Type: Article

References (22)

1. Nutt JG & Wooten GF. Diagnosis and initial management of Parkinson's disease. New England Journal of Medicine 2005 353 1021-1027.
2. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ & Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotoninergic medication. Circulation 2000 102 2836-2841.
3. B receptors is not a class effect of the ergolines. European Journal of Pharmacology 2005 513 225-228.
4. Roth BL. Drugs and valvular heart disease. New England Journal of Medicine 2007 356 6-9.
5. Schade R, Andersohn F, Suissa S, Haverkamp W & Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine 2007 356 29-38.
6. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine 2007 356 39-46.
7. Pinero A, Marcos-Alberca P & Fortes J. Cabergoline-related severe restrictive mitral regurgitation. New England Journal of Medicine 2005 353 1976-1977.
8. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C & Schoors D. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004 363 1179-1183.
9. Casanueva F, Molitch ME, Schlechte J, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA & Giustina A. Department of Medicine, Endocrine Division Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clinical Endocrinology 2006 65 265-273.
10. Schlechte JA. Clinical practice. Prolactinoma. New England Journal of Medicine 2003 349 2035-2041.
11. Daly A, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross sectional study in the province of Liège, Belgium. Journal of Clinical Endocrinology and Metabolism 2006 91 4769-4775.
12. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C & Beckers A. Department of Endocrinology. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism 1999 84 2518-2522.
13. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A & Weissman NJ. American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. Journal of the American Society of Echocardiography 2003 16 777-802.
14. Lancellotti P, Lebrun F & Pierard LA. Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction. Journal of the American College of Cardiology 2003 42 1921-1928.
15. Pierard LA & Lancellotti P. The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. New England Journal of Medicine 2004 351 1627-1634.
16. FDA Public Health Advisory: Pergolide. March 29th, 2007. http://www.fda.gov/cder/drug/advisory/pergolide.htm.
17. Sherlock M, Steeds R & Toogood AA. Dopamine agonist therapy and cardiac valve dysfunction. Clinical Endocrinology 2007 67 643-644.
18. Kim JY, Chung EJ, Park SW & Lee WY. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Movement Disorders 2006 21 1261-1264.
19. Mah PM & Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Seminars in Reproductive Medicine 2002 20 365-374.
20. Serri O, Chik CL, Ur E & Ezzat S. Diagnosis and management of hyperprolactinemia. Canadian Medical Association Journal 2003 169 575-581.
21. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R & Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. New England Journal of Medicine 2003 349 2023-2033.
22. Barlier A & Jaquet P. Quinagolide - a valuable treatment option for hyperprolactinaemia. European Journal of Endocrinology 2006 154 187-195.